Which stock will you Buy? RXi Pharmaceuticals Corporation (RXII) or Halliburton Company (HAL)

The shares of RXi Pharmaceuticals Corporation (NASDAQ:RXII) and Halliburton Company (NYSE:HAL) were among the active stocks of the last trading sessions. RXi Pharmaceuticals Corporation (NASDAQ:RXII) soared to 4.17% closing at the price of $0.63 whereas the shares of Halliburton Company (NYSE:HAL) soared 0.26% with the increase of 0.11 points closing at the price of $42. RXi Pharmaceuticals Corporation has currently decrease -79.1% in its stock over the period of 6-months while its rival Halliburton Company subtracted -9.79% in the previous 6-months.

Now we have to analyze the facts that if the stocks were worthy off investors’ money? The facts to analyze here are risks, profitability, returns and price trends.

Returns and Profitability

Profitability and returns are the main reason of investment, the investors are looking for profits that they get and return they should expect over the period of time.

The first and foremost return that is considered while making an investment is the ROI or Return on Investment. The ROI is the ratio between the profit against the cost of investment. Currently the ROI of RXi Pharmaceuticals Corporation (NASDAQ:RXII) is 0% while the ROI of Halliburton Company (NYSE:HAL) is 5.2%. Another figure that is to be considered while analyzing the profitability of a share is its EBITDA margin, RXII’s EBITDA Margin is -0.03 whereas HAL’s is 10.18.

Both the profitability ratios suggest that Halliburton Company (NYSE:HAL) is more suitable investment in terms of profitability and return.

EPS & Surprise Factor

RXi Pharmaceuticals Corporation (NASDAQ:RXII) reported $-0.46/share EPS for the previous quarter where analysts were predicting an EPS to be $-0.62/share Thus beating the analyst Estimates with a Surprise Factor of 25.8 Percent. While, Halliburton Company (NYSE:HAL) reported EPS of $0.58/share in the last quarter. The analysts projected EPS of $0.58/share depicting a Surprise of 0 Percent.

Taking a look at Earnings per Share, RXi Pharmaceuticals Corporation tends to be beating the analyst estimates more than Halliburton Company. so RXII is more profitable than HAL.

Technical Analysis of RXi Pharmaceuticals Corporation & Halliburton Company

Moving average convergence divergence (MACD) shows that RXi Pharmaceuticals Corporation (NASDAQ:RXII) is on a PRICE RELATIVITY trend While Halliburton Company (NYSE:HAL) is on PRICE RELATIVITY trend. The trend for the past 10-days shows that the RXi Pharmaceuticals Corporation was in BEARISH territory and Halliburton Company was in BULLISH territory.

RXII’s current statistics gauge that the stock candle is BULLISH with HIGH volatility. While HAL’s candle is BULLISH with LOW.

EPS Growth Rate: RXII’s 0% versus HAL’s 44.7%

Another shareholder value can be analyzed through the EPS growth rate; the next 5 years EPS growth rate is predicted by the analysts after the analyzing the previous trends. The next 5 year EPS growth rate of RXi Pharmaceuticals Corporation (NASDAQ:RXII) is predicted at 0% while Halliburton Company (NYSE:HAL) stands at 44.7%. These numbers suggest that HAL is more suitable investment in terms of EPS growth rate.

Financial Risk and Liquidity Concerns

The current ratio and the debt ratio are the two ratios that show the investor how quickly the company is able to payout its debt and how quickly it can cover its obligations. The current ratio of RXII stands at 2.1 while HAL is at 2.2 whereas the debt ratio of the prior is 0 while the debt ratio of the later is 1.23.

The values of the both ratios suggest that HAL is more suitable investment when the liquidity and risk is the main concern.

Analyst Recommendations

While making an investment, another main factor to consider before investing is the analyst recommendation on the scale of 1 to 5 where 1 is strong buy, 2 is buy, 3 is hold, 4 is Sell and 5 is strong sell. Analyst recommend 2 for RXII and 1.8 for HAL which means RXII has Buy rating whereas HAL has Buy rating.

Another recommendation of analyst that is to be considered worthy is the price target. The mare price or price trend does not suggest the suitability of a stock. The price target set by analyst is also to be considered while investing as it suggests to what extent the stock will rise or fall in the near future. The price target set for RXII is $3 which is 79% of its current price while HAL has price target of 51.5 which is 18.45% of its current price.

Valuation Ratios

Valuation is the process of determining the company’s worth for an investor, the valuation ratios give an insight to that worthiness.

RXII currently has price to earning P/E ratio of 0 whereas HAL has 41.54 while the forward P/E ratio for the prior stands at 0 and for the later it depicts the value of 16.83.

The price to Book P/B for RXII is 0.78, Price to Sale is at 27.08 and for HAL these ratios stand at 4.17 and 1.58.